Evidence mapPaperPMID 42516653Full record

ArticleMedical journal of the Islamic Republic of Iran2026

Effect of Comorbidities on In-hospital COVID-19 Mortality across Age Groups: A Retrospective Cohort Study in Iran.

Reza Sadeghi, Mahmood Reza Masoudi, Mohammad Moqaddasi Amiri

Abstract read
In one paragraph

Article in Medical journal of the Islamic Republic of Iran, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Reza SadeghiDepartment of Public Health, Sirjan School of Medical Sciences, Sirjan, Iran.
Mahmood Reza MasoudiDepartment of Internal Medicine, Division of Rheumatology, Sirjan School of Medical Sciences, Sirjan, Iran.
Mohammad Moqaddasi AmiriDepartment of Public Health, Sirjan School of Medical Sciences, Sirjan, Iran.ORCID https://orcid.org/0000-0002-8003-7123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COVID-19 has emerged as one of the most significant healthcare challenges globally in recent years, affecting numerous individuals and resulting in fatalities, particularly among older adults and those with comorbidities. While the influence of comorbidities on mortality in COVID-19 patients has been explored in various studies, it has not been examined across different age groups. We evaluated the impact of comorbidities on COVID-19 mortality in three distinct age groups. Methods: A total of 10,496 hospitalized patients with positive PCR results for COVID-19 in Sirjan city were included in the study. Underlying conditions, including diabetes, hypertension, cardiovascular disease, and chronic kidney disease, were documented alongside age, sex, and COVID-19 status. The chi-square test and logistic regression were employed to assess the impact of comorbidities on mortality across different age groups. Results: A total of 2,038 (19.4%) patients had at least one comorbidity. The number of deaths from COVID-19 was 466 (4.4%), of which 197 had comorbidities. Hypertension and diabetes were the most prevalent underlying conditions among COVID-19 patients, occurring in 11.9% and 8.6% of cases, respectively. The presence of comorbidities was significantly associated with mortality in the overall population (OR=3.26, 95% CI: 2.69-3.94) as well as in individuals aged between 30 and 60 years (OR=2.63, 95% CI: 1.77-3.91) and those over 60 years (OR=1.58, 95% CI: 1.26-1.99). Furthermore, the number of comorbidities influenced the mortality rate among COVID-19 patients (OR=1.65 for two comorbidities and OR=1.97 for three or more comorbidities compared to patients with one comorbidity), although it did not vary across different age groups. Conclusion: Comorbidities can influence the mortality rate associated with COVID-19 among individuals aged 30, particularly within the 30-60 year age group. While the presence of multiple comorbidities significantly elevates the risk of death in the overall population, this association was not found to be statistically significant when analyzed by age group.

Indexed as

Age GroupsComorbiditiesCOVID-19 MortalityRisk of MortalityUnderlying Disease

Identifiers

PMID42516653
PMCPMC13404230

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.